医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

s COVID-19 continues to put immense pressure on global supply chains making family planning access more critical than ever, DKT International, one of the largest providers of sexual and reproductive health products and services in the developing world, commits to the Family Planning 2030 movement (FP2030). Through both financial and direct services, DKT has pledged to generate 400 million non-abortion Couple Years Protection (CYPs) across more than 90 countries between 2021 and 2030. The organization will also invest $1 billion of discretionary resources, including the procurement of commodities, between 2021 and 2030.…　続きを読む

创新型分子诊断解决方案开发商SpeeDx Pty. Ltd.推出新款研究试剂产品线，以支持针对传播型SARS-CoV-2“需关注变异株”(VOC)的翻卷型变异株分析。PlexPrime® SARS-CoV-2基因分型*检测试剂的快速推进将支持调查和监测新发传播型SARS-CoV-2 VOC的范围。这些VOC具有传播性更强、对现有疫苗抗性更强等特征，可能需要特定的公共卫生行动来应对。1 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20210728005716/zh-CN/SpeeDx的独家技术在突变检测应用中表现出色，而且已能用于SARS-CoV-2序列数据库中报告的变异株。PlexPrime® SARS-CoV-2基因分型研究试剂与标准qPCR仪器兼容，能通过识别需要注意的样本、帮助聚焦下游活动并最终缩短实验室周转和手工操作时间来减少为测序分析制备阳性样本的手工流程。（照片：美国商业资讯） SpeeDx首席技术官Elisa Mokany表示：“利用我们的独家通用型基材方法，我们的快速响应开发团队能轻松应对新冠肺炎持续大流行所导致的不断变化的复杂情况。我们的独家技术在突变检测应用中表现出色，而且已能用于SARS-CoV-2序列数据库中报告的变异毒株。” PlexPrime ® SARS-CoV-2 Alpha/Beta/Gamma+*是该产品系列中的首款产品。这是一种单孔套检产品，旨在检测B.1.1.7 (Alpha)、B.1.351 (Beta)和P.1 (Gamma) VOC中所发现的SARS-CoV-2刺突基因的N501Y、S982A和E484K突变。针对德尔塔VOC相关突变的第二款套检产品也将很快发布，针对其他突变的产品目前正在评估之中。上述检测试剂与标准qPCR仪器兼容，能通过识别需要注意的样本、帮助聚焦下游活动并最终缩短实验室周转和手工操作时间来减少为测序分析制备阳性样本的手工流程。…　続きを読む

mmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced that Adrian Woolfson, BM BCh, PhD, has joined its Board of Directors and Scientific Advisory Board to help guide the company’s strategy as it expands into drug discovery.…　続きを読む

NYO Pharma (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced that Vonafexor met the primary and several secondary endpoints in the LIVIFY clinical study conducted in F2-F3 Non Alcoholic Steato-Hepatitis (NASH) patients.…　続きを読む